Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age–related macular degeneration: real world data from the Fight Retinal Blindness registry

[1]  Y. Kurimoto,et al.  Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR , 2020, Advances in Therapy.

[2]  P. Mitchell,et al.  The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. , 2019, Survey of ophthalmology.

[3]  R. Guymer,et al.  Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. , 2019, Ophthalmology.

[4]  R. Guymer,et al.  Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial , 2019, JAMA ophthalmology.

[5]  P. Jaki Mekjavić,et al.  Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia , 2018, BMC Ophthalmology.

[6]  Aaron Y. Lee,et al.  Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors , 2018, Progress in Retinal and Eye Research.

[7]  H. Tanihara,et al.  Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration , 2018, Acta ophthalmologica.

[8]  A. Ho,et al.  Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. , 2017, American journal of ophthalmology.

[9]  K. Tsaousis,et al.  24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting , 2017, BMC Ophthalmology.

[10]  A. Lotery,et al.  One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration , 2017, Eye.

[11]  R. Guymer,et al.  Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. , 2015, Ophthalmology.

[12]  R. Guymer,et al.  Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. , 2015, Ophthalmology.

[13]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[14]  C. Bunce,et al.  The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. , 2014, Ophthalmology.

[15]  R. Guymer,et al.  Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. , 2014, Ophthalmology.

[16]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[17]  J. Keeffe,et al.  EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES: The Fight Retinal Blindness! Project , 2014, Retina.

[18]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[19]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[20]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[21]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[22]  A Hofman,et al.  Risk factors for age-related macular degeneration: Pooled findings from three continents. , 2001, Ophthalmology.

[23]  Benjamin Friedman,et al.  MECHANICS OF OPTIC NERVE TRACTION ON THE RETINA DURING OCULAR ROTATION: WITH SPECIAL REFERENCE TO RETINAL DETACHMENT , 1941 .

[24]  Michael Larsen,et al.  Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. , 2018, Ophthalmology.

[25]  R. Guymer,et al.  TWO YEAR OUTCOMES OF “TREAT AND EXTEND” INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2018, Retina.

[26]  L. Sandvik,et al.  Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. , 2016, Ophthalmology.

[27]  Glenn J Jaffe,et al.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.

[28]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[29]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.